Pricing Log in Create free account
Friday 6 November 2026 Export ENVB’s income statement to Excel — free account

Enveric Biosciences, Inc.

ENVB Healthcare Biotechnology

EPS
+93.5%
Free cash flow
−29.3%

Quarter to June 2026, against a year earlier

1.42 0.02 +1.43%
Market cap
$6.3M
P/E
0.0×
Fwd P/E
−3.6×
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
−4.74
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 6.26
Revenue ttm 35.41
Net income ttm (8.73)
Free cash flow ttm (8.56)
Net debt Q (8.30)
Valuation
P/E 0.00
Forward P/E (3.57) (negative: loss-making)
Price / sales 0.16
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.70
Financial health
Current ratio Q 10.21 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (10,091.33)
Growth
Revenue growth Q −7.28% (below 0%: shrinking)
Operating income growth Q −20.18% (below 0%: shrinking)
EPS, this year +38.66% (at or above 15%: strong)
EPS, next year A +25.86% (at or above 15%: strong)
Revenue, next year A −100.00% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −0.1×, against a ten-year median of 0.3×; over the ten years it ranged from −0.5× in 2022 to 48,809,147× in 2016.
P/S against its own 10 years 33.65%
10-year low 10-year high
P/B against its own 10 years 30.31%
10-year low 10-year high
EV/FCF against its own 10 years 50.20%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 2 2 5 8
Receivables — — — —
Inventory — — — —
Other — — — —
4 3 5 9
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other 0 0 — —
2 1 1 1

Compound Annual Growth %

10y 5y 3y
Sales — — 3.36%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 32.08% 4.11% (34.21%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY24 Estimate −93.59 Actual −43.20

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY23 −278.97 −262.77 Beat by 16.20
Q1 FY24 −109.79 −109.79 Met by 0.00
Q2 FY24 −98.99 −45.00 Beat by 53.99
Q3 FY24 −93.59 −43.20 Beat by 50.39

EPS $

Mar Jun Sep Dec Year
’26 (1.08) (0.76) — — —
’25 (14.65) (11.64) (10.81) (6.13) (36.24)
’24 (109.79) (45.00) (43.20) (57.46) (228.57)
’23 (415.76) (547.14) (233.98) (262.77) (1.46k)
’22 (989.90) (491.35) (262.77) (880.11) (2.34k)
’21 (1.80k) (382.95) (1.06k) (15.57k) (18.63k)
’20 (1.75k) (1.30k) (867.88) (6.82k) (10.71k)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 11 11 9 — —
’18 11 11 11 10 43
’17 12 12 13 11 49
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (2) (2) (2) (8)
’24 (3) (3) (1) (1) (8)
’23 (5) (4) (3) (2) (14)
’22 (5) (5) (5) (3) (17)
’21 (3) (2) (2) (4) (11)
’20 (1) 0 0 (2) (4)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (2) (2) — — —
’25 (2) (2) (2) (2) (8)
’24 (3) (3) (1) (1) (8)
’23 (5) (4) (3) (2) (14)
’22 (5) (5) (5) (3) (18)
’21 (3) (2) (2) (4) (12)
’20 (1) 0 0 (2) (4)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 36 49 43 — — — — — — — 35 +9.1% 5 — — —
Gross margin, % 19.17 21.07 20.89 20.42 0.00 0.00 0.00 — — — 0.00 (19.2) pt
EBT (7) (11) (11) (2) (7) (56) (20) (17) (10) (9) (9) +3.3%
EBT margin, % (18.05) (23.60) (24.53) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 +18.1 pt
Net income (3) (9) (19) (2) (7) (49) (18) (17) (10) (9) (9) +13.6%
Per share, $
Per share, $ Revenue 2.77 3.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 n/m
Earnings (0.21) (0.75) (737,926.40) (4,103.25) (10,708.93) (18,628.14) (2,339.77) (1,456.05) (228.57) (36.24) (18.78) +77.0%
Cash flow (0.21) (0.18) 0.00 (1,079.83) (6,481.33) (4,406.81) (2,143.34) (1,174.53) (184.39) (24.32) (2.15) +69.8%
Capex 0.00 0.00 0.00 (140.50) 0.00 (72.96) (73.02) 0.98 0.00 0.00 0.00 n/m
Free cash flow (0.21) (0.18) 0.00 (1,220.33) (6,481.33) (4,479.77) (2,216.36) (1,173.56) (184.39) (24.32) (2.15) +69.6%
Book value 0.89 1.30 0.00 (3,019.33) 5,692.67 8,579.19 1,833.99 163.03 38.01 12.48 2.03 +34.1%
Shares, m 13 15 0 0 0 0 0 0 0 0 2 (33.4%)
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 — — — — — — 0.00 0.0
P/S 31,776,179.26 12,862,075.64 0.00 18.35 — — — — — — 0.16 11,159,568.3
P/B 98,504,220.80 32,144,241.44 0.00 0.00 — — — — — — 0.70 32,662,115.6
EV/Sales 31,776,179.74 12,862,075.69 0.12 18.47 — — — — — — (0.07) 11,159,568.5
EV/FCF (420,244,075.32) (159,593,454.87) (1.09) (258.97) — — — — — — 0.22 (144,959,447.6)
Cash, $m
Cash, $m Operating cash flow (3) (3) (3) (1) (4) (11) (17) (14) (8) (8) (9) +13.0%
Capex 0 0 0 0 0 0 (1) 0 — — 0 n/m
Free cash flow (3) (3) (3) (1) (4) (12) (18) (14) (8) (8) (9) +12.9%
Balance, $m
Balance, $m Working capital (3) (16) (5) (2) 2 15 14 1 1 4 8 n/m
Net debt 17 2 4 0 (2) (17) (18) (2) (2) (5) (8) n/m
Shareholders’ equity 12 19 11 (2) 3 22 15 2 2 4 8 (10.8%)
Returns, %
Returns, % ROA (10.43) (24.35) (47.61) (16.21) (326.45) (317.87) (81.26) (146.39) (259.40) (296.67) (193.53) (286.2) pt
ROIC (11.63) (31.31) (30.60) 0.00 (191.11) (815.97) 0.00 0.00 0.00 0.00 0.00 +11.6 pt
ROE (46.66) (71.78) (129.02) (53.93) (875.21) (381.31) (101.68) (209.99) (539.57) (420.48) (235.48) (373.8) pt
People
People Employees 237 417 390 397 3 24 26 7 6 6 — (33.5%)
Revenue/emp, $m 0.15 0.12 0.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2018 · latest quarter Sep 2019 · fundamentals updated 26 Oct 2026

Enveric Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
SYBX Synlogic, Inc. $6.7M — (loss-making) — (loss-making) −95.40% (below 0%: shrinking) n/m −277.87% (below 0%: shrinking) 100.00% 0.00% Compare
KPRX Kiora Pharmaceuticals, Inc. $6.6M — (loss-making) — (loss-making) −93.64% (below 0%: shrinking) n/m +50.06% (above 0%: growing) 100.00% 0.00% Compare
FBLG FibroBiologics Inc. $6.4M — (loss-making) — — n/m +21.59% (above 0%: growing) — 0.00% Compare
ENVB Enveric Biosciences, Inc. $6.3M — (loss-making) — (loss-making) −7.28% (below 0%: shrinking) n/m −29.34% (below 0%: shrinking) 0.00% 0.00%
APRE Aprea Therapeutics, Inc. $6.2M — (loss-making) — (loss-making) −98.40% (below 0%: shrinking) n/m −5.22% (below 0%: shrinking) 100.00% 0.00% Compare
AIM AIM ImmunoTech Inc. $6.1M — (loss-making) — (loss-making) +4.00% (above 0%: growing) n/m −167.46% (below 0%: shrinking) 80.77% (13,511.54%) Compare
EVGN Evogene Ltd. $6.0M — (loss-making) — (loss-making) −35.02% (below 0%: shrinking) n/m +17.72% (above 0%: growing) 40.63% (738.62%) Compare
CNSP CNS Pharmaceuticals, Inc. $5.9M — (loss-making) — — n/m +33.70% (above 0%: growing) 0.00% 0.00% Compare
XCUR Exicure, Inc. $5.8M — (loss-making) — (loss-making) −80.51% (below 0%: shrinking) n/m +65.38% (above 0%: growing) 100.00% 0.00% Compare
Median of peers $6.2M — — −87.07% — +19.66% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 14 April 2026

Ownership

Directors and executive officers, together 2.41%
Lind Global Fund III LP et al. 7.40%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Enveric Biosciences, Inc. (ENVB) Latest News

21 Oct

Impact 4 · · Business Wire
Impact 3 · · Benzinga

15 Sep

Impact 3 ·

5 Aug

Impact 4 ·

28 Jul

Impact 4 ·

2 Jun

Impact 3 · · Business Wire

19 May

Impact 3 · · Business Wire

15 May

Impact 3 ·

13 May

Impact 4 · · Business Wire

17 Apr

Impact 4 · · Business Wire

16 Apr

Impact 4 · · Business Wire

31 Mar

Impact 4 · · Business Wire

27 Mar

Impact 3 · · Business Wire

25 Feb

Impact 4 · · Business Wire

20 Feb

Impact 3 · · TipRanksProactive

19 Feb

Impact 3 · · Business Wire

29 Jan

Impact 4 · · Business Wire

30 Dec

Impact 4 · · TipRanks

29 Dec

Impact 4 · · Business WireMarket ExclusiveInsider MonkeyInsider MonkeySimply Wall St.MT Newswires

12 Dec

Impact 3 · · Business Wire

11 Dec

Impact 3 · · Business Wire

10 Dec

Impact 3 · · Associated Press Finance

9 Dec

Impact 4 · · Business Wire

4 Dec

Impact 3 · · Business WireGuruFocus.com

26 Nov

Impact 4 · · Business Wire

14 Nov

Impact 3 · · Business Wire

23 Oct

Impact 3 · · Business Wire

16 Oct

Impact 4 · · Business WireInvesting.comGuruFocus.comMT Newswires

15 Oct

Impact 4 · · GuruFocus.comMT NewswiresMT NewswiresInsider MonkeyInsider Monkey
Impact 3 · · Investing.com
stockrow.com/ENVB · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com